Clone of CB 399: CRISPR-Cas Systems and the Future of Genome Editing

CRISPR-Cas Systems and the Future of Genome Editing

Course Description
Clustered regularly interspaced short palindromic repeat (CRISPR) RNAs and their CRISPR-associated (Cas) proteins are an important part of adaptive immune systems in many prokaryotes. CRISPR-Cas systems function as RNA-directed endonucleases that can target nucleic acids in a sequence-specific manner and are now widely used as genome editing tools. In this course, we will provide lectures covering: an introduction to genome editing and cutting-edge improvements to CRISPR-Cas systems; a review of bioinformatics tools for guide RNA design and analysis of CRISPR-Cas data; and an overview of on-going and potential therapeutic applications of genome-editing nucleases. The course will also include a practical lab-based workshop for registered students in which participants will learn how to design guide RNAs and how to perform the broadly useful TIDE assay that enables quantification of nuclease-induced mutations in any cell or organism.

Nanocourse Director: J. Keith Joung
Curriculum Fellow: Emily Gleason (emily_gleason@hms.harvard.edu)

Lecturers
• J. Keith Joung, MD, PhD, Professor of Pathology, Harvard Medical School and Pathologist, Massachusetts General Hospital
• Luca Pinello, PhD, Instructor in Medicine, Massachusetts General Hospital Department of Pathology
• Morgan Maeder, PhD, Scientist, Editas Medicine

Session Dates and Times
Session 1: Lectures (open to all without prior registration)

DATE CHANGE!!!!

Date: Thursday, November 10th 9:30 am to 1:00 pm
Location: Armenise Amphitheater

Session 2: Practical lab-based workshop (limited to registered students)
Date: Wednesday, November 16th 1:00 pm to 5:00 pm
Location: Joung Lab - 149 13th Street, Charlestown, MA

Assignment
Complete analysis of a TIDE experiment designed to assess mutation frequency induced by a CRISPR-Cas nuclease at an endogenous human gene target site.

Note: registration will close at noon on Tuesday, 11/2.